APOLLOMICS INC-27 (APLMW) Stock News

USA - NASDAQ:APLMW -

0.0152 USD

0 (-3.18%)

Last: 9/12/2025, 8:00:01 PM

0.0152 USD

0 (0%)

After Hours: 9/12/2025, 8:00:01 PM

Technical Analysis

APLMW Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill - Mentions: NBY SUPX NVFY AIHS ...

News Image

Top movers analysis one hour before the close of the markets on 2025-09-05: top gainers and losers in today's session.

9 days ago - By: Chartmill - Mentions: NBY AEO SCVL NCI ...

News Image

Which stocks are gapping on Thursday?

11 days ago - By: Chartmill - Mentions: CYTK MNKD UTHR IONS ...

News Image

There are notable gap-ups and gap-downs in today's session.

15 days ago - By: Chartmill - Mentions: WOOF MOVE SOS NEO ...

News Image

Top movers in Friday's session

16 days ago - By: Chartmill - Mentions: IGC WOOF MOVE MRVL ...

News Image

Top movers in Thursday's after hours session

16 days ago - By: Chartmill - Mentions: CVM MB PSTG MBRX ...

News Image

Thursday's session: top gainers and losers

5 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

5 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

6 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

6 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

9 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics 公布在中国对复发或难治性急性髓系白血病患者进行的 Uproleselan III 期桥接试验主要结果

9 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics 公布 Uproleselan 在中國治療復發或難治性急性髓系白血病患者的第 3 期銜接性試驗的主要結果

9 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

9 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

9 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

10 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

10 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement